Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2025-07-14 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
2025年半年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2025 年半年度业绩预告' which translates to '2025 Half-Year Performance Forecast'. It provides estimated financial results for the period January 1, 2025 to June 30, 2025, including expected net profit losses and earnings per share. It explicitly states that the forecast has not been audited and that the actual financial data will be disclosed in the official half-year report. The document is short (1122 characters) and serves as a preliminary earnings forecast rather than a full interim report containing actual financial statements or detailed analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. H1 2025
2025-07-14 Chinese
2025年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2025 second extraordinary shareholders meeting of the company. It details the meeting attendance, voting results, and legal witness statements. It does not contain full financial statements or detailed financial performance data. The document is primarily a formal announcement of voting results from a shareholders meeting, not the meeting materials or presentations themselves. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, consistent with DVA filings.
2025-07-14 Chinese
关于部分监事、高级管理人员减持期限届满暨未减持公司股份的公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding the expiration of the shareholding reduction period for certain supervisors and senior management personnel and the fact that they did not reduce their holdings. It includes details about the planned and actual share reductions, compliance with relevant securities laws and regulations, and references to related disclosure documents. There are no financial statements, earnings data, or detailed management analysis. The document is primarily about insider shareholding activity and compliance with disclosure rules. This fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is moderate and contains detailed shareholding information, not just a brief notice or a report publication announcement. Therefore, the correct classification is DIRS with high confidence.
2025-07-11 Chinese
关于持股5%以上股东完成证券非交易过户的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a non-trade transfer of shares held by a shareholder owning more than 5% of the company's stock. It details the transfer of shares from one shareholder to others, the percentage of total shares involved, and confirms that the control of the company remains unchanged. The document includes specific shareholder names, share quantities, and compliance with prior commitments related to shareholding and reduction. It is a formal disclosure about changes in significant share ownership levels, not a financial report or earnings release. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or announcement of a report publication.
2025-07-09 Chinese
关于召开2025年第二次临时股东会的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the convening of the company's 2025 second extraordinary general meeting of shareholders (临时股东会). It includes information about the meeting date, voting procedures (both onsite and online), registration details, agenda items, and proxy forms. The document does not contain financial statements or results but serves as a notice and procedural guide for the shareholders' meeting. It is not a report of voting results, nor is it a proxy solicitation statement, but rather a meeting notice and instructions for participation. Given the content and length (4258 characters), it fits best as a regulatory announcement related to shareholder meetings but not the meeting materials themselves or voting results. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-09 Chinese
董事会关于本次重大资产重组信息发布前公司股票价格波动情况的说明
Capital/Financing Update Classification · 95% confidence The document is a statement from the board of directors of a company regarding stock price fluctuations before a major asset restructuring announcement. It discusses stock price data and clarifies that the price movement did not constitute abnormal fluctuations. There is no detailed financial report, audit, or earnings data. The document is an announcement related to a corporate transaction and stock price behavior, not a full report or financial statement. It fits best under Capital/Financing Update (CAP) as it relates to a major asset sale and associated stock price information.
2025-06-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.